[CITATION][C] A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with …
H Richly, P Kupsch, K Passage… - … journal of clinical …, 2003 - pubmed.ncbi.nlm.nih.gov
A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006
administered in combination with doxorubicin in patients with solid tumors A phase I clinical and
pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in
combination with doxorubicin in patients with solid tumors Int J Clin Pharmacol Ther. 2003
Dec;41(12):620-1. doi: 10.5414/cpp41620. Authors H Richly 1 , P Kupsch, K Passage, M Grubert,
RA Hilger, S Kredtke, D Voliotis, ME Scheulen, S Seeber, D Strumberg Affiliation 1 University of …
administered in combination with doxorubicin in patients with solid tumors A phase I clinical and
pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in
combination with doxorubicin in patients with solid tumors Int J Clin Pharmacol Ther. 2003
Dec;41(12):620-1. doi: 10.5414/cpp41620. Authors H Richly 1 , P Kupsch, K Passage, M Grubert,
RA Hilger, S Kredtke, D Voliotis, ME Scheulen, S Seeber, D Strumberg Affiliation 1 University of …